← Leaderboards
George Tellides
Yale University
$10,774,220
Attributed
$17,714,152
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,714,152 · 11
By mechanism
R01$10,106,208 · 5
P01$4,662,546 · 3
U01$2,193,773 · 1
R21$460,625 · 1
R56$291,000 · 1
Top collaborators
- Jay D Humphrey13 shared
- Jordan S Pober9 shared
- W Mark Saltzman7 shared
- Michael Simons4 shared
Most similar at Yale University
Same institution · by research overlap
- Jay D Humphrey$27,724,941
- Jordan S Pober$30,894,969
- Vikki Abrahams$10,204,254
- Carlos Alberto Figueroa$2,970,173
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsResponseSignal TransductionMouse ModelBlood VesselsMolecularAortaSmooth Muscle MyocytesEndothelial CellsArteriesInflammationPhenotypeChronicTissuesPreventProteinsSignal PathwayLeukocytesT-LymphocyteMacrophageTransplantationImmuneImmunodeficient MouseGenes
Grant awards (43)
ELUCIDATING MECHANISMS OF THORACIC AORTOPATHY VIA COMPUTATIONAL MODELING$669,807
R01 · FY2025 · HL
Modeling Multiscale Immuno-Mechanics in Aortic Disease$491,820
R01 · FY2025 · HL
TGFb-Dependent Cell-Matrix Interactions in Thoracic Aortopathy$358,300
P01 · FY2025 · HL · contact PI
Vascular smooth muscle cell heterogeneity and disease$817,799
R01 · FY2024 · HL
ELUCIDATING MECHANISMS OF THORACIC AORTOPATHY VIA COMPUTATIONAL MODELING$705,944
R01 · FY2024 · HL
Modeling Multiscale Immuno-Mechanics in Aortic Disease$488,551
R01 · FY2024 · HL
Vascular smooth muscle cell heterogeneity and disease$831,140
R01 · FY2023 · HL
Modeling Multiscale Immuno-Mechanics in Aortic Disease$491,820
R01 · FY2023 · HL
Vascular smooth muscle cell heterogeneity and disease$830,638
R01 · FY2022 · HL
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$652,823
R01 · FY2022 · HL · contact PI
Modeling Multiscale Immuno-Mechanics in Aortic Disease$500,195
R01 · FY2022 · HL
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$47,570
R01 · FY2022 · HL · contact PI
Vascular smooth muscle cell heterogeneity and disease$826,040
R01 · FY2021 · HL
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$773,693
R01 · FY2021 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$489,354
U01 · FY2021 · AI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$29,419
U01 · FY2021 · AI
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$652,821
R01 · FY2020 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2020 · AI
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$73,300
R01 · FY2020 · HL · contact PI
Smooth Muscle Cell Proliferation and Degradative Phenotype in Thoracic Aorta Aneurysm and Dissection$652,821
R01 · FY2019 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2019 · AI
Combined Human Myeloid and Lymphoid Engraftment in MISTRG Mice for Transplantation Research$209,375
R21 · FY2019 · AI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2018 · AI
Combined Human Myeloid and Lymphoid Engraftment in MISTRG Mice for Transplantation Research$251,250
R21 · FY2018 · AI
Characterization of TGFB-Dependent Mechanoresponses by Aortic Smooth Muscle Cells$599,426
R01 · FY2017 · HL · contact PI
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium$418,750
U01 · FY2017 · AI
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection$291,000
R56 · FY2013 · AI
IFN-gamma, smooth muscle cells and graft arteriosclerosis$531,003
P01 · FY2010 · HL · contact PI
Core--Microsurgery$221,726
P01 · FY2010 · HL · contact PI
IFN-gamma, smooth muscle cells and graft arteriosclerosis$515,548
P01 · FY2009 · HL · contact PI
Core--Microsurgery$215,267
P01 · FY2009 · HL · contact PI
IFN-gamma, smooth muscle cells and graft arteriosclerosis$490,528
P01 · FY2008 · HL · contact PI
Core--Microsurgery$204,813
P01 · FY2008 · HL · contact PI
IFN-gamma, smooth muscle cells and graft arteriosclerosis$490,824
P01 · FY2007 · HL · contact PI
Core--Microsurgery$204,936
P01 · FY2007 · HL · contact PI
IFN-gamma, smooth muscle cells and graft arteriosclerosis$484,514
P01 · FY2006 · HL · contact PI
Core--Microsurgery$202,305
P01 · FY2006 · HL · contact PI
Core--Microsurgery$193,924
P01 · FY2005 · HL
IFN gamma in human GA$193,924
P01 · FY2005 · HL
Core--Microsurgery$177,467
P01 · FY2002 · HL
IFN gamma in human GA$177,467
P01 · FY2002 · HL
Core--Microsurgery$0
P01 · FY2001 · HL
IFN gamma in human GA$0
P01 · FY2001 · HL